ArticleInternational journal of molecular medicine2015
Shikonin reduces TGF-β1-induced collagen production and contraction in hypertrophic scar-derived human skin fibroblasts.
Article in International journal of molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Global trends and hotspots of natural medicines for pathological scar treatment: a visualized bibliometric analysis (2008-2025).Frontiers in medicine · 2026Pooled it
- Evidence-based therapy in hypertrophic scars: An update of a systematic review.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2020Pooled it
- The role of thrombospondin-1 in dermatological conditions.Frontiers in medicine · 2026Review
- Chrysin inhibits hypertrophic scar formation through TGF-β/Smad signaling pathways.Journal of molecular histology · 2025Article
- Revealing the Mechanisms of Shikonin Against Diabetic Wounds: A Combined Network Pharmacology and In Vitro Investigation.Journal of diabetes research · 2025Article
- Comparative Efficacy ofMolecules (Basel, Switzerland) · 2024Article
- Natural products for the treatment of hypertrophic scars: Preclinical and clinical studies.Heliyon · 2024Review
- Pharmacotherapy for Keloids and Hypertrophic Scars.International journal of molecular sciences · 2024Review
- Gallic Acid Treats Hypertrophic Scar in Rabbit Ears via the TGF-β/Smad and TRPC3 Signaling Pathways.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Shikonin promotes hypertrophic scar repair by autophagy of hypertrophic scar-derived fibroblasts.Acta cirurgica brasileira · 2023Article
- USP15 Enhances the Proliferation, Migration, and Collagen Deposition of Hypertrophic Scar-Derived Fibroblasts by Deubiquitinating TGF-βR1 In Vitro.Plastic and reconstructive surgery · 2021Observational
- Transdermal delivery of Chinese herbal medicine extract using dissolvable microneedles for hypertrophic scar treatment.Acta pharmaceutica Sinica. B · 2021Article
- Improvement of skin lesions in corticosteroid withdrawal-associated severe eczema by multicomponent traditional Chinese medicine therapy.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2021Article
- Shikonin reduces hepatic fibrosis by inducing apoptosis and inhibiting autophagy via the platelet-activating factor-mitogen-activated protein kinase axis.Experimental and therapeutic medicine · 2021Article
- Smad‑binding decoy reduces extracellular matrix expression in human hypertrophic scar fibroblasts.Molecular medicine reports · 2020Article
- Biological approaches for hypertrophic scars.International wound journal · 2020Review
- Plants of the GenusFrontiers in pharmacology · 2020Review
- MicroRNA-26a inhibits hyperplastic scar formation by targeting Smad2.Experimental and therapeutic medicine · 2018Article
- A novel regulatory function for miR-217 targetedly suppressing fibronectin expression in keloid fibrogenesis.International journal of clinical and experimental pathology · 2018Article
- Development of a Porcine Full-Thickness Burn Hypertrophic Scar Model and Investigation of the Effects of Shikonin on Hypertrophic Scar Remediation.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic scarring/hypertrophic scars (HS) is a highly prevalent condition following burns and trauma wounds. Numerous studies have demonstrated that transforming growth factor-β1 (TGF‑β1) plays an essential role in the wound healing process by regulating cell differentiation, collagen production and extracellular matrix degradation. The increased expression of TGF-β1 is believed to result in the formation of HS. Shikonin (SHI), an active component extracted from the Chinese herb, Radix Arnebiae, has previously been found to downregulate the expression of TGF-β1 in keratinocyte/fibroblast co-culture conditioned medium. In view of this, in this study, we aimed to further investigate the effects of SHI on TGF-β1-stimulated hypertrophic scar-derived human skin fibroblasts (HSFs) and examined the underlying mechanisms. Cell viability and proliferation were measured using alamarBlue and CyQUANT assays. The total amount of collagen and cell contraction were examined using Sirius red staining and the cell contraction assay kit. Gene expression and signalling pathway activation were detected using reverse transcription-quantitative polymerase chain reaction and western blot analysis. Our results revealed that SHI reduced TGF-β1‑induced collagen production through the ERK/Smad signalling pathway and attenuated TGF-β1‑induced cell contraction by downregulating α-smooth muscle actin (αSMA) expression in the HSFs. The data from this study provide evidence supporting the potential use of SHI as a novel treatment for HS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.